{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:31:54Z","timestamp":1793467914968,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009242","name":"DGOS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016130","name":"D\u00e9partement de la Sant\u00e9 des For\u00eats","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009243","name":"Direction G\u00e9n\u00e9rale de l\u2019offre de Soins","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.msard.2025.106858","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:17:47Z","timestamp":1763036267000},"page":"106858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Non-inferiority of Rituximab versus OCrelizumab in Multiple Sclerosis (ROC-MS)\u2014an individual participant data meta-analysis"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9845-5031","authenticated-orcid":false,"given":"Lisa G.","family":"Schoof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brit Ellen","family":"R\u00f8d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahla","family":"El Mahdaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine S.","family":"Michelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar A.","family":"H\u00f8gest\u00f8l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell-Morten","family":"Myhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning H.","family":"Rise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Friede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Lundell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Sellebjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karam","family":"Sidaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartwig Roman","family":"Siebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Wiggermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Jasperse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Lissenberg-Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob W.","family":"van Oosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno M.","family":"Schoonheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Edan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malo","family":"Gaubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Le Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Kerbrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.M.","family":"Strijbis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ivind","family":"Torkildsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeppe Romme","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106858_bib0001","doi-asserted-by":"crossref","unstructured":"Alharbi M.A., Aldosari F., Althobaiti A.H., et al. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia. BMC Health Serv. Res.;23(1):552. doi:10.1186\/s12913-023-09462-z.","DOI":"10.1186\/s12913-023-09462-z"},{"issue":"6","key":"10.1016\/j.msard.2025.106858_bib0002","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/ana.26914","article-title":"Real-world healthcare cost savings and reduced relapse rate with off-label rituximab versus disease-modifying treatments approved for relapsing-remitting multiple sclerosis: a nationwide cost-effectiveness study","volume":"95","author":"Alping","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106858_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1473284","article-title":"Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis","volume":"15","author":"Alvarez","year":"2024","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106858_bib0004","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106858_bib0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/ane.12963","article-title":"Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?","volume":"138","author":"Berntsson","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2025.106858_bib0006","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2046-4053-1-2","article-title":"The nuts and bolts of PROSPERO: an international prospective register of systematic reviews","volume":"1","author":"Booth","year":"2012","journal-title":"Syst. Rev."},{"issue":"9","key":"10.1016\/j.msard.2025.106858_bib0007","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1177\/1352458518760717","article-title":"Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary","volume":"24","author":"Cree","year":"2018","journal-title":"Mult Scler."},{"issue":"3","key":"10.1016\/j.msard.2025.106858_bib0008","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/EDE.0000000000001177","article-title":"Toward causally interpretable meta-analysis: transporting inferences from multiple randomized trials to a new target population","volume":"31","author":"Dahabreh","year":"2020","journal-title":"Epidemiology"},{"issue":"2","key":"10.1016\/j.msard.2025.106858_bib0009","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/biom.13716","article-title":"Efficient and robust methods for causally interpretable meta-analysis: transporting inferences from multiple randomized trials to a target population","volume":"79","author":"Dahabreh","year":"2023","journal-title":"Biometrics"},{"key":"10.1016\/j.msard.2025.106858_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106400","article-title":"Early extended interval dosing of rituximab in multiple sclerosis: a comparative cohort study on efficacy and safety","volume":"97","author":"Fossum","year":"2025","journal-title":"Mult Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2025.106858_bib0011","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1474-4422(08)70192-3","article-title":"B cells and multiple sclerosis","volume":"7","author":"Franciotta","year":"2008","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.msard.2025.106858_bib0014","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2025.106858_bib0012","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.msard.2025.106858_bib0013","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2025.106858_bib0015","article-title":"No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a","volume":"4","author":"Havrdova","year":"2018","journal-title":"Mult Scler. J. Exp. Transl. Clin."},{"issue":"9805","key":"10.1016\/j.msard.2025.106858_bib0016","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2025.106858_bib0017","article-title":"Potential medicare and medicaid savings on anti-CD20 therapy for multiple sclerosis","author":"Kim","year":"2023","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106858_bib0018","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.msard.2025.106858_bib0019","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208063","article-title":"Rituximab for multiple sclerosis: hiding in plain sight","volume":"102","author":"Langer-Gould","year":"2024","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/j.msard.2025.106858_bib0020","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1212\/WNL.0b013e3181e24373","article-title":"Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial","volume":"74","author":"Naismith","year":"2010","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2025.106858_bib0021","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1177\/1352458518757930","article-title":"Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes","volume":"24","author":"Piehl","year":"2018","journal-title":"Mult Scler."},{"key":"10.1016\/j.msard.2025.106858_bib0024","doi-asserted-by":"crossref","DOI":"10.1177\/09622802251380624","article-title":"Center-specific causal inference with multicenter trials\u2014Interpreting trial evidence in the context of each participating center","author":"Robertson","year":"2025","journal-title":"Statistical Methods in Medi. Res."},{"key":"10.1016\/j.msard.2025.106858_bib0022","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2023.1625","article-title":"Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis","author":"Roos","year":"2023","journal-title":"JAMA Neurol."},{"issue":"20","key":"10.1016\/j.msard.2025.106858_bib0023","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106858_bib0025","doi-asserted-by":"crossref","first-page":"l5342","DOI":"10.1136\/bmj.l5342","article-title":"A guide to prospective meta-analysis","volume":"367","author":"Seidler","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.msard.2025.106858_bib0026","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13063-020-04984-x","article-title":"Quantifying the advantages of conducting a prospective meta-analysis (PMA): a case study of early childhood obesity prevention","volume":"22","author":"Seidler","year":"2021","journal-title":"Trials"},{"issue":"8","key":"10.1016\/j.msard.2025.106858_bib0027","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","article-title":"Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial","volume":"21","author":"Svenningsson","year":"2022","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.msard.2025.106858_bib0028","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/1352458518757931","article-title":"Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No","volume":"24","author":"Wallin","year":"2018","journal-title":"Mult Scler."},{"issue":"3","key":"10.1016\/j.msard.2025.106858_bib0029","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209610","article-title":"Efficacy of ofatumumab and teriflunomide in patients with relapsing MS from racial\/ethnic minority groups: ASCLEPIOS I\/II subgroup analyses","volume":"103","author":"Williams","year":"2024","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:29:22Z","timestamp":1781076562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825006005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"alternative-id":["S2211034825006005"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106858","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-inferiority of Rituximab versus OCrelizumab in Multiple Sclerosis (ROC-MS)\u2014an individual participant data meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106858"}}